RFK Jr. opens door to peptide telehealth boom
Source: Axios
Kennedy's regulatory push to relax peptide restrictions creates a direct commercial opportunity for telehealth platforms like GoodRx and Ro, which have already built infrastructure to distribute compounded medications at scale. The move mirrors how ketamine clinics and GLP-1 distribution networks captured consumer spend by operating in regulatory gray zones—except peptides, used for muscle building and anti-aging, appeal to a broader wellness market than psychiatric or weight-loss drugs. If peptides move from black-market fitness supplements to FDA-adjacent telehealth products, the winner is not the wellness industry broadly but the companies with existing prescriber networks and patient data that can convert curiosity into recurring revenue.